YC Companies/Winter 2021/Trestle Biotherapeutics
Trestle Biotherapeutics logo

Trestle Biotherapeutics

Bioengineered kidneys for patients with kidney failure

Winter 2021Healthcare / Healthcare -> Industrial BioSan Diego, CA, USA2 employees
Biotech

About

We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.

Build your own investing agent

GPAgent keeps YC listings public and neutral. Fund-specific scoring, notes, and workflow state live in each customer workspace.

Join the GPAgent waitlist

Founders (2)

Alice Chen
Founder
Ben Shepherd
Founder

Details

Status
Active
Stage
Early
Team Size
2
Regions
United States of America, America / Canada